- After landmark deal, AstraZeneca goes to CSPC again in up to $1.7B pactLess than six months after lining up one of the largest biobucks packages in industry history, AstraZeneca is returning to the same Chinese partner for another drug R&D collaboration. The UK…Endpoints · 22d ago↗ source
- Court halts Colorado price cap on Amgen's blockbuster EnbrelUS District Court Judge Daniel Domenico in Colorado granted Amgen's preliminary injunction to stop a 70% price cap on its blockbuster autoimmune drug Enbrel, arguing that the cap could cause "econo…Endpoints · 22d ago↗ source
- Revolution Medicines shares promising data around KRAS drug combinationRevolution Medicines on Thursday gave a first look at the early-stage data that led it to plan a Phase 3 trial combining two KRAS drugs in pancreatic cancer. One of the two drugs is a ...